<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176185</url>
  </required_header>
  <id_info>
    <org_study_id>MT-16</org_study_id>
    <nct_id>NCT04176185</nct_id>
  </id_info>
  <brief_title>A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber</brief_title>
  <acronym>QUEST</acronym>
  <official_title>A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Adult Chinese Subjects With HDM Allergic Rhinitis/Rhinoconjunctivitis Using an Environmental Exposure Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the efficacy and safety of HDM SLIT-tablet in treatment of HDM AR. The
      efficacy is evaluated using an environmental exposure chamber (EEC). Subjects will be
      randomised to receive treatment with HDM SLIT-tablet and placebo 1:1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a 24 weeks, randomised, parallel-group, double-blind, placebo-controlled phase
      III trial. Approximately 202 subjects will be randomised (1:1) to receive treatment with HDM
      SLIT-tablet or placebo. The trial will be conducted in China, with subjects recruited and
      treated in China. Two EEC assessments (baseline and end of treatment) will take place at a
      validated EEC facility in Austria.

      The primary objective is to demonstrate the efficacy of the HDM SLIT-tablet (12 SQ-HDM) once
      daily compared to placebo in the treatment of HDM AR nasal symptom determined during the EEC
      session at week 24.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">November 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomised</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Score (TNSS)</measure>
    <time_frame>Last 4 hours of the EEC session at week 24</time_frame>
    <description>Primary endpoint, average TNSS during the EEC session at week 24, defined as the average of all TNSS observed in the last 4 hours of the EEC session at week 24. Measured on a scale of 0 (no symptoms) to 12 (severe symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score (TSS)</measure>
    <time_frame>Last 4 hours of the EEC session at week 24</time_frame>
    <description>Key secondary endpoint, average TSS during the EEC session at week 24, defined as the sum of the Total Ocular Symptom Score (TOSS) and TNSS observed in the last 4 hours of the EEC session at week 24. Measured on a scale of 0 (no symptoms) to 18 (severe symptoms).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of Adverse events per treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of lung function</measure>
    <time_frame>26 weeks</time_frame>
    <description>FEV1</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Ocular Symptom Score (TOSS)</measure>
    <time_frame>Last 4 hours of the EEC session at week 24</time_frame>
    <description>Average TOSS during the EEC session at week 24, defined as the average of all TOSS observed in the last 4 hours of the EEC session at week 24. Measured on a scale of 0 (no symptoms) to 6 (severe symptoms).</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunology</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Change from baseline in measurements of house-dust-mite-specific IgG &amp; IgE antibodies</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDM SLIT-tablet once daily for approximately 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once daily for approximately 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sublingual allergy immunological tablet</intervention_name>
    <description>For daily administration (1 tablet per day)</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>12 SQ HDM SLIT-tablet</other_name>
    <other_name>Acarizax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For daily administration (1 tablet per day)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo sublingual tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male or female Chinese subjects aged ≥18 years

          -  A clinical history of HDM AR/C with or without asthma

          -  Positive SPT and IgE to Der p or Der f at screening

          -  A TNSS of at least 6 of 12 within the first 2 hours of the screening EEC session prior
             to randomisation

        Exclusion criteria

          -  Sensitised and regularly exposed perennial or seasonal allergens

          -  Asthma requiring treatment with high-dose ICS

          -  Reduced lung function

          -  Has a nasal condition that could confound the efficacy or safety assessment

          -  A relevant history of systemic allergic reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luo Zhang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette K Laursen, MSc</last_name>
    <phone>+4545747576</phone>
    <email>clinicaltrials@alk.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin R Pedersen, MSc</last_name>
    <phone>+4545747576</phone>
    <email>clinicaltrials@alk.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Challenge Chamber</name>
      <address>
        <city>Vienna</city>
        <zip>1150</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René Zieglmayer, CEO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lou Zhang, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>House Dust Mite</keyword>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Allergic conjunctivitis</keyword>
  <keyword>China</keyword>
  <keyword>Environmental exposure chamber</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

